Observational studyInternal medicine journal2026
Maintenance intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: trends from an Australian tertiary centre.
Observational study in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is commonly treated with long-term intravenous immunoglobulin (IVIg). Individual dosing requirements and duration of IVIg differ among patients, leading to significant heterogeneity in IVIg utilisation.
aimsWe aimed to report on IVIg treatment trends in CIDP patients at our centre and sought to determine whether any clinical or demographic factors were predictive of a successful treatment wean.
methodsThis retrospective observational study included adults receiving maintenance IVIg for CIDP over a 5-year period across a hospital network in South Australia. Overall, IVIg maintenance requirements were described across the cohort. Patient characteristics, investigations and IVIg usage were recorded. These factors were compared between those who had successfully weaned IVIg and those who had not.
resultsTwenty-two patients were included, with 82% meeting European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria for definite CIDP. Seventeen had typical CIDP, with a mean age of 58 and a male-to-female ratio of 2:1. Average body mass index was 30 kg/m
conclusionClinical stability was achieved for most patients on ≤0.6 g/kg/4 weeks of IVIg. Many individuals did not undergo an IVIg wean, highlighting the need for more proactive consideration of dose reduction or treatment cessation trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.